GoodRx (GDRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended September 2024, GoodRx Holdings, Inc. (GDRX) reported revenue of $195.25 million, up 8.5% over the same period last year. EPS came in at $0.08, compared to $0.06 in the year-ago quarter.The reported revenue represents a surprise of -0.05% over the Zacks Consensus Estimate of $195.35 million. With the consensus EPS estimate being $0.09, the EPS surprise was -11.11%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how GoodRx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Monthly Active Consumers: 7 compared to the 6 average estimate based on three analysts. Subscribers: 701 versus 701 estimated by two analysts on average. Revenue- Prescription transactions: $140.40 million compared to the $140.72 million average estimate based on five analysts. The reported number represents a change of +3.7% year over year. Revenue- Pharma Manufacturer Solutions: $28.10 million versus $27.44 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +76.7% change. Revenue- Subscription: $21.30 million versus the five-analyst average estimate of $21.42 million. The reported number represents a year-over-year change of -8.4%. View all Key Company Metrics for GoodRx here>>>Shares of GoodRx have returned -13.1% over the past month versus the Zacks S&P 500 composite's +3.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Free Today: Profiting from The Future’s Brightest Energy SourceThe demand for electricity is growing exponentially. At the same time, we’re working to reduce our dependence on fossil fuels like oil and natural gas. Nuclear energy is an ideal replacement.Leaders from the US and 21 other countries recently committed to TRIPLING the world’s nuclear energy capacities. This aggressive transition could mean tremendous profits for nuclear-related stocks – and investors who get in on the action early enough.Our urgent report, Atomic Opportunity: Nuclear Energy's Comeback, explores the key players and technologies driving this opportunity, including 3 standout stocks poised to benefit the most.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GoodRx Holdings, Inc. (GDRX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks